排序方式:
    總頁 1 
      Go

    1.Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes: an update

    Tomlinson, B, Chan,     More...

    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2024, Volume 20, Issue 4, Pages 175-179

    收錄情况: WOS SCOPUS

    WOS核心合集引用:  2023影響因子:  3.9 

    2.What is the impact of type 2 diabetes mellitus on CYP450 metabolic activities?

    Tomlinson, B, Li, YH

    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2023, Volume 19, Issue 12, Pages 867-870

    收錄情况: WOS SCOPUS

    WOS核心合集引用:  2023影響因子:  3.9  发表年影響因子:  3.9 

    3.An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease

    Tomlinson, B, Chow,     More...

    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2021, Volume 17, Issue 12, Pages 1353-1361

    收錄情况: WOS SCOPUS

    WOS核心合集引用:  2023影響因子:  3.9  发表年影響因子:  4.936 

    4.Pharmacokinetics of current and emerging treatments for hypercholesterolemia

    Tomlinson, B, Chan,     More...

    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2020, Volume 16, Issue 5, Pages 371-385

    收錄情况: WOS SCOPUS

    WOS核心合集引用:  2023影響因子:  3.9  发表年影響因子:  4.481 

    5.Metformin transporter pharmacogenomics: insights into drug disposition-where are we now?

    Chan, P, Shao, L, To     More...

    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2018, Volume 14, Issue 11, Pages 1149-1159

    收錄情况: WOS SCOPUS

    WOS核心合集引用: 16  2023影響因子:  3.9  发表年影響因子:  3.487 

    6.Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes

    Tomlinson, B, Hu, M,     More...

    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2017, Volume 13, Issue 2, Pages 211-223

    收錄情况: WOS SCOPUS

    WOS核心合集引用: 16  2023影響因子:  3.9  发表年影響因子:  3.151 

    7.Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes

    Tomlinson, B, Hu, M,     More...

    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2016, Volume 12, Issue 11, Pages 1267-1271

    收錄情况: WOS SCOPUS

    WOS核心合集引用: 10  2023影響因子:  3.9  发表年影響因子:  3.027 

    8.Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin

    Hu, M, Tomlinson, B

    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2014, Volume 10, Issue 1, Pages 51-65

    收錄情况: WOS SCOPUS

    WOS核心合集引用: 33  2023影響因子:  3.9  发表年影響因子:  2.831 

    9.The pharmacogenetics of beta-adrenergic receptor antagonists in the treatment of hypertension and heart failure

    Chan, SW, Hu, M, Tom     More...

    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2012, Volume 8, Issue 7, Pages 767-790

    收錄情况: WOS SCOPUS

    WOS核心合集引用: 14  2023影響因子:  3.9  发表年影響因子:  2.944 

    10.The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins

    Hu, MA, To, KKW, Mak     More...

    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2011, Volume 7, Issue 1, Pages 49-62

    收錄情况: WOS SCOPUS

    WOS核心合集引用: 41  2023影響因子:  3.9  发表年影響因子:  3.119 

    11.Pharmacokinetic evaluation of lanreotide

    Hu, MA, Tomlinson, B

    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2010, Volume 6, Issue 10, Pages 1301-1312

    收錄情况: WOS SCOPUS

    WOS核心合集引用: 12  2023影響因子:  3.9  发表年影響因子:  3.374 

    顯示      條  合計   11   條
      總頁 1 
        Go

      本系統需要使用 Internet Explorer 9.0 以上Firefox || Chrome瀏覽器

      Copyright © 2018 澳門科技大學學者庫